Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trialMüge Çevik, Borisov Se, Lindsay C Thompson et al.|The Lancet Infectious Diseases|2024Cited by 60
MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical ConcentrationKelly Wallace Stinson, Lawrence Geiter, Masanori Kawasaki et al.|Antimicrobial Agents and Chemotherapy|2016Cited by 57